Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-02-03
1998-12-08
Walsh, Stephen
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514912, 514914, 530325, A61K 3808
Patent
active
058469400
DESCRIPTION:
BRIEF SUMMARY
This application is the U.S. National stage of PCT/JP95/01549 filed Aug. 4, 1995.
TECHNICAL FIELD
The present invention relates to a corneal therapeutic agent, and more particularly, to a corneal therapeutic agent which accelerates the healing of the cornea after photon rendering keratectomy using an ultraviolet laser, especially, an excimer laser, and which prevents corneal opacity.
BACKGROUND ART
In the ophthalmic field, it has been recently studied to cure paropsia by geometrical incision of an eye. The corneal incision is employed to cure, for example, ametropia such as myopia, hyperopia, and astigmatism and corneal disorders such as corneal opacity. The surgical treatment mentioned above is quite advantageous in respect that the permanent correction can be realized, compared to conventional eyesight-correction methods using compensating lenses such as glasses or contact lenses.
As a representative example of the surgical treatment for paropsia, there is a myopia therapy by means of keratectomy. In particular, radial keratotomy, one of the surgical treatment methods for ametropia, is used for correcting myopia caused by excessive corneal arcuation. In this method, cutting is made along the radial lines extending outwardly from a center of the cornea, usually with a surgical knife. The depth of the cutting is generally about 90 to 95% of the cornea thickness. The number of the cutting lines is possibly in the range of 4-16, generally, 8-12. The corneal incision mentioned above makes the cornea relaxed and slightly flattened, thereby mitigating or overcoming the myopia.
Besides this, photon rendering keratectomy (PRK) using an excimer laser is known. In the PRK method, the central portion of a corneal front face is cut off to form a depressed portion. The cornea is cut off in the form of a meniscus. In an infrared laser such as a carbonate gas laser or a YAG laser, molecules constituting an irradiated object absorb a laser beam, causing molecular vibration. Heat generated by the molecular vibration melts and cuts the object. In the excimer laser, however, photon energy cuts the bonds of the molecules constituting the irradiated object. As a result, the cornea is rarely denatured with heat. In addition, the laser can process the object precisely, so that only required region of the cornea can be cut off accurately to a necessary depth.
However, if the cornea is not completely cured after any surgery, the phenomena called white corneal opacity, namely keratoleukoma, will occur in some cases. The keratoleukoma is caused by random secretion of collagen to the corneal surface during a wound-healing stage. The random collagen secretion is induced by the stimulation of the cornea with an excimer laser or the like during a surgical operation.
DISCLOSURE OF THE INVENTION
It is an object of the present invention to provide a corneal therapeutic agent capable of preventing keratoleukoma by accelerating the curing of a cornea after the surgical operation of ametropia.
The present invention provides a corneal therapeutic agent comprising at least one of a hexapeptide and a pharmacologically acceptable salt thereof (hereinafter, referred to as "HP") represented by formula (I) shown below, and a pharmacologically acceptable carrier, deaminated, alkylated or acylated; B is L- or D-arginine, lysine or hystidine; Pro is L- or D-proline; C is L- or D-tyrosine, tryptophane, or phenylalanine; D is L- or D-valine, isoleucine, or leucine having an amino group whose hydrogen atom may be substituted with an alkyl group having 1 to 4 carbon atoms; E is L- or D-valine, isoleucine or leucine having a C-terminal carboxylic group which is unsubstituted or substituted with --COOR, --CH.sub.2 OR or --CONHR, where R represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.
The corneal therapeutic agent is developed for curing a corneal wound and preventing corneal opacity, i.e., keratoleukoma, and is used in these uses.
The corneal therapeutic agent may further contain at least one of an epithelial cell growth fa
REFERENCES:
patent: 5145680 (1992-09-01), Hayashi
patent: 5348939 (1994-09-01), Horowitz et al.
patent: 5360611 (1994-11-01), Robertson et al.
patent: 5360789 (1994-11-01), Nakao et al.
patent: 5374612 (1994-12-01), Ito et al.
patent: 5374621 (1994-12-01), Wei
patent: 5393740 (1995-02-01), Amagaya et al.
Amagaya Sakae
Kanitani Masanao
Okamoto Sinseiro
Sakamoto Kenji
Lazar-Wesley Eliane
Okamoto Sinseiro
Walsh Stephen
LandOfFree
Corneal therapeutic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Corneal therapeutic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Corneal therapeutic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177300